BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes

• Published in: International urology and nephrology Vol. 28; no. 4; p. 499
• Main Authors: Melekos, M D, Zarakovitis, I, Dandinis, K, Fokaefs, E, Chionis, H, Dauaher, H, Barbalias, G
• Format: Journal Article
• Language: English
• Published: Netherlands 1996
• Subjects: Adjuvants, Immunologic - therapeutic use; Administration, Intravesical; Aged; Antibiotics, Antineoplastic - therapeutic use; BCG Vaccine - administration & dosage; BCG Vaccine - therapeutic use; Disease-Free Survival; Epirubicin - therapeutic use; Female; Humans; Immunotherapy; Male; Neoplasm Recurrence, Local - prevention & control; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - mortality; Urinary Bladder Neoplasms - therapy

A prospective randomized trial on 94 eligible patients evaluated and compared the efficacy of adjuvant intravesical epirubicin and bacillus Calmette-Guérin (BCG) after complete resection of multifocal superficial bladder cancer. BCG treatment schedule consisted of an induction 6-week course of insti...